Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Associate

Erika J. Pey

Goodwin Procter

main

Pey Erika

Goodwin Associate Erika Pey, from New York City, practices in Business Law with an emphasis on tax.

Erika J. Pey

Areas of Practice

Professional Activities

Credentials

Education

JD2022

BS2019

Admissions

Bars

Related Content

Current Issues for Qualified Small Business Stock — How New R&E Expensing Rules Could Hurt Your QSBS Status, and Why Cash Management Changes Likely Won’t

Zealand and Roche Form Largest Single Asset Partnership Deal Worth up to $5.3 billion to Co-Develop and Co-Commercialize Petrelintide Monotherapy and Potential Combination Products in the U.S. and Europe as Therapy for Obesity

Goodwin Advises Sionna Therapeutics on the Closing of its $219.2 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

BlueHalo To Be Acquired By AeroVironment In $4.1 Billion All-Stock Transaction

Goodwin Advises StepStone as Lead Investor in Transaction with Gemspring

Goodwin Advises Curon Biopharmaceutical in Acquisition of CN201 by Merck for $700 Million Upfront Plus up to $600 Million Milestones

Renesas Completes Acquisition of Transphorm

Proteologix to be Acquired by Johnson & Johnson For $850 Million

Mariana Oncology To Be Acquired by Novartis For $1 Billion Upfront, And Up To $750 Million in Milestones

Tax